Catalyst Wire Dossier Catalyst Wire Dossier

Amgevita

adalimumab · Amgen Europe B.V.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Amgevita, covering 2026-04-23 to 2026-08-18. Get the full timeline:

Most recent: EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.

See pricing